
Quarterly report 2025-Q3
added 11-13-2025
Avenue Therapeutics Long-Term Debt 2011-2026 | ATXI
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Avenue Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 2.03 M | 2.7 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.7 M | 2.03 M | 2.36 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M | ||
|
Xeris Pharmaceuticals
XERS
|
220 M | $ 6.03 | -1.55 % | $ 885 M | ||
|
I-Mab
IMAB
|
68.2 M | - | - | $ 866 M | ||
|
UroGen Pharma Ltd.
URGN
|
122 M | $ 19.2 | -11.52 % | $ 554 M | ||
|
uniQure N.V.
QURE
|
49.7 M | $ 10.89 | -30.36 % | $ 530 M | ||
|
GT Biopharma
GTBP
|
64 K | $ 0.47 | -2.41 % | $ 892 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M | ||
|
AbCellera Biologics
ABCL
|
137 M | $ 3.74 | 3.6 % | $ 1.12 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M | ||
|
Adverum Biotechnologies
ADVM
|
86 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - | ||
|
ARCA biopharma
ABIO
|
755 K | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
146 K | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
3.38 M | - | - | $ 2.17 B | ||
|
Acorda Therapeutics
ACOR
|
167 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
410 K | - | 4.01 % | $ 150 M | ||
|
CureVac N.V.
CVAC
|
25.4 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
31 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
13.2 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
9.12 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
2.63 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
12.8 M | $ 3.36 | 0.86 % | $ 1.2 M | ||
|
Ayala Pharmaceuticals
AYLA
|
1.33 M | - | - | $ 7.46 M | ||
|
Akero Therapeutics
AKRO
|
529 K | - | - | $ 3.67 B | ||
|
Agios Pharmaceuticals
AGIO
|
21.8 M | $ 29.16 | -3.54 % | $ 1.69 B | ||
|
Advaxis
ADXS
|
8.14 M | - | -9.65 % | $ 45.9 M | ||
|
Akouos
AKUS
|
28.3 M | - | 0.23 % | $ 488 M | ||
|
Завод ДИОД
DIOD
|
7.45 M | - | - | - | ||
|
Фармсинтез
LIFE
|
13.2 M | - | - | - | ||
|
Albireo Pharma
ALBO
|
9.62 M | - | -0.23 % | $ 916 M | ||
|
Alector
ALEC
|
9.32 M | $ 2.19 | -9.77 % | $ 226 M | ||
|
Entera Bio Ltd.
ENTX
|
3.89 M | $ 1.38 | -0.72 % | $ 63.3 M | ||
|
Allena Pharmaceuticals
ALNA
|
210 K | - | 3.16 % | $ 1.9 M | ||
|
Aileron Therapeutics
ALRN
|
69 K | - | 10.36 % | $ 9.8 M | ||
|
Altimmune
ALT
|
1.4 M | $ 4.21 | -2.32 % | $ 299 M | ||
|
Teligent, Inc.
TLGT
|
137 M | - | -13.85 % | $ 16.1 M | ||
|
AlloVir
ALVR
|
16.6 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | ||
|
Amarin Corporation plc
AMRN
|
6.08 M | $ 13.98 | 1.27 % | $ 5.7 B | ||
|
AbbVie
ABBV
|
64.5 B | $ 233.57 | 0.64 % | $ 413 B | ||
|
Blueprint Medicines Corporation
BPMC
|
68.8 M | - | - | $ 8.14 B | ||
|
Applied Molecular Transport
AMTI
|
49 K | - | - | $ 10.1 M | ||
|
AIM ImmunoTech
AIM
|
659 K | $ 0.8 | -11.6 % | $ 38.5 M | ||
|
Aptorum Group Limited
APM
|
130 K | $ 0.83 | 5.37 % | $ 4.53 M | ||
|
Apellis Pharmaceuticals
APLS
|
93.3 M | $ 20.67 | -1.38 % | $ 2.61 B |